Advertisement
Screener

Pacific Biosciences of California, Inc. (PACB) Amortization of Intangible Assets

2.8 / 5 stars · 68/120 Roast Me

Pacific Biosciences of California, Inc. Amortization of Intangible Assets

Pacific Biosciences of California, Inc. (PACB) reported Amortization of Intangible Assets of $1.02 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AmortizationOfIntangibleAssets · last filed 2026-05-08

  • Pacific Biosciences of California, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $1.02M, a 99.72% decline year-over-year.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $1.02M, a 85.13% decline year-over-year.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $1.02M, a 85.11% decline year-over-year.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for the quarter ending 2025-06-30 was $1.02M, a 85.13% decline year-over-year.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for fiscal 2025 was $369.45M, a 1247.76% increase from fiscal 2024.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for fiscal 2024 was $27.41M, a 231.82% increase from fiscal 2023.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for fiscal 2023 was $8.26M, a 804.82% increase from fiscal 2022.
  • Pacific Biosciences of California, Inc. amortization of intangible assets for fiscal 2022 was $913.00K.
Period endAmortization of Intangible Assets 3 monthAmortization of Intangible Assets 6 monthAmortization of Intangible Assets 9 monthAmortization of Intangible Assets 12 monthAmortization of Intangible Assets 12 month as first filed
2026-03-31$1.02M
10-Q · filed 2026-05-08
$2.04M
derived: sum of 2 quarters · filed 2026-05-08
$3.06M
derived: sum of 3 quarters · filed 2026-05-08
$4.08M
derived: sum of 4 quarters · filed 2026-05-08
2025-12-31$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$2.04M
derived: sum of 2 quarters · filed 2026-02-25
$3.06M
derived: sum of 3 quarters · filed 2026-02-25
$369.45M
10-K · filed 2026-02-25
2025-09-30$1.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$2.04M
derived: sum of 2 quarters · filed 2025-11-06
$368.43M
10-Q · filed 2025-11-06
$375.28M
derived: sum of 4 quarters · filed 2026-05-08
2025-06-30$1.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$367.41M
10-Q · filed 2025-08-07
$374.26M
derived: sum of 3 quarters · filed 2026-05-08
$381.12M
derived: sum of 4 quarters · filed 2026-05-08
2025-03-31$366.39M
10-Q · filed 2026-05-08
$373.24M
derived: sum of 2 quarters · filed 2026-05-08
$380.10M
derived: sum of 3 quarters · filed 2026-05-08
$386.95M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$6.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$13.71M
derived: sum of 2 quarters · filed 2026-02-25
$20.56M
derived: sum of 3 quarters · filed 2026-02-25
$27.41M
10-K · filed 2026-02-25
2024-09-30$6.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$13.71M
derived: sum of 2 quarters · filed 2025-11-06
$20.56M
10-Q · filed 2025-11-06
$27.41M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$6.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$13.71M
10-Q · filed 2025-08-07
$20.56M
derived: sum of 3 quarters · filed 2026-02-25
$21.50M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$6.85M
10-Q · filed 2025-05-12
$13.71M
derived: sum of 2 quarters · filed 2026-02-25
$14.65M
derived: sum of 3 quarters · filed 2026-02-25
$14.88M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$6.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$7.79M
derived: sum of 2 quarters · filed 2026-02-25
$8.03M
derived: sum of 3 quarters · filed 2026-02-25
$8.26M
10-K · filed 2026-02-25
$6.16M
10-K · filed 2024-02-28
2023-09-30$942.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$1.17M
derived: sum of 2 quarters · filed 2024-11-12
$1.41M
10-Q · filed 2024-11-12
$1.64M
derived: sum of 4 quarters · filed 2025-03-17
2023-06-30$232.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
$466.00K
10-Q · filed 2024-08-09
$694.00K
derived: sum of 3 quarters · filed 2025-03-17
$923.00K
derived: sum of 4 quarters · filed 2025-03-17
2023-03-31$234.00K
10-Q · filed 2024-05-09
$462.00K
derived: sum of 2 quarters · filed 2025-03-17
$691.00K
derived: sum of 3 quarters · filed 2025-03-17
$919.00K
derived: sum of 4 quarters · filed 2025-03-17
2022-12-31$228.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17
$457.00K
derived: sum of 2 quarters · filed 2025-03-17
$685.00K
derived: sum of 3 quarters · filed 2025-03-17
$913.00K
10-K · filed 2025-03-17
$900.00K
10-K · filed 2023-02-28
2022-09-30$229.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
$457.00K
derived: sum of 2 quarters · filed 2023-11-03
$685.00K
10-Q · filed 2023-11-03
2022-06-30$228.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
$456.00K
10-Q · filed 2023-08-04
2022-03-31$228.00K
10-Q · filed 2023-05-04
2021-12-31$0.00
10-K · filed 2024-02-28
$400.00K
10-K · filed 2022-02-28
2020-12-31$0.00
10-K · filed 2023-02-28
2019-12-31$0.00
10-K · filed 2022-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
908 Devices Inc. (MASS)United States$0.476B-9.53
EyePoint, Inc. (EYPT)United States$0.314B-3.96
Cytek Biosciences, Inc. (CTKB)United States$0.744B-7.15
Quanterix Corp (QTRX)United States$0.150B-1.65
Nautilus Biotechnology, Inc. (NAUT)United States$0.129B-4.16
Seer, Inc. (SEER)United States$0.104B-1.34
Precipio, Inc. (PRPO)United States$0.043B-36.70
HARVARD BIOSCIENCE INC (HBIO)United States$0.037B-2.70
Bionano Genomics, Inc. (BNGO)United States$0.020B-0.42
ASTROTECH Corp (ASTC)United States$0.013B